← Back to Search

Latozinemab Continuation for Neurodegenerative Disease

Phase 3

Waitlist Available

Research Sponsored by Alector Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Female participants must be nonpregnant and nonlactating

Male participants must agree to acceptable contraception use

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, up to 190 weeks

Awards & highlights

Study Summary

This trial extends access to a medication to those who have already taken part in a related study.

Who is the study for?

This trial is for people who have already been in a Latozinemab study. They must be able to give consent, not pregnant or breastfeeding, and willing to use contraception. People with severe allergies to certain proteins, significant heart, liver or kidney disease, brain diseases other than FTD, or those on immunosuppressive therapy can't join.Check my eligibility

What is being tested?

The trial provides continued access to Latozinemab for participants from previous studies of the drug. It's designed to see if ongoing treatment remains safe and effective over a longer period.See study design

What are the potential side effects?

Latozinemab may cause allergic reactions due to its protein nature. Other potential side effects are not detailed but could be similar to those experienced during the initial trials.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am not pregnant or breastfeeding.

Select...

I agree to use contraception.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, up to 190 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, up to 190 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, up to 190 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Duration of treatment with latozinemab

Number of participants receiving latozinemab

Secondary outcome measures

Incidence of ADAs to latozinemab

Incident of adverse events (AEs) and serious adverse events (SAEs)

Nature and severity of AEs and SAEs

Trial Design

1Treatment groups

Experimental Treatment

Group I: Open LabelExperimental Treatment1 Intervention

Latozinemab (AL001) administered by IV infusion over 60 minutes, q4w

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineIndustry Sponsor

4,751 Previous Clinical Trials

8,067,437 Total Patients Enrolled

Alector Inc.Lead Sponsor

10 Previous Clinical Trials

1,250 Total Patients Enrolled

Megan SmitheyStudy DirectorAlector Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What security protocols are in place for Open Label usage?

"Our analysts at Power have judged Open Label's safety to be a 3 as this is currently an advanced-stage trial, indicating that there has been ample data backing its efficacy and security."

Answered by AI

Are there still open slots for volunteers to join this research project?

"Affirmative. Clinicaltrials.gov's records suggest that this clinical trial is currently seeking volunteers, which was initially posted on October 9th 2023. The last update occurred on October 30th 2023 and 35 participants are necessary between two locations."

Answered by AI

How many individuals are being included in this research endeavor?

"Affirmative, the clinicaltrial.gov data reveals that this research is actively recruiting patients. First posted on October 9th 2023 and last updated on 30th of the same month, it aims to find 35 participants from 2 locations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Continuation Study for Latozinemab

2023. "Continuation Study for Latozinemab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06111014.